Consumer Health: Treating polycystic ovary syndrome
Polycystic ovary syndrome is a hormonal disorder common among women of reproductive age. Complications can include infertility, gestational diabetes or pregnancy-induced high blood pressure, miscarriage or premature birth, and endometrial cancer. Signs and symptoms of polycystic ovary syndrome vary. A diagnosis is made when women experience at least two of these signs: Irregular periods.Elevated levels of male [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 11, 2021 Category: Databases & Libraries Source Type: news

Pembrolizumab in dMMR/MSI-H unresectable or metastatic endometrial cancer: substantial gain in life-years at acceptable cost in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - April 2021
GSK’s Checkpoint Inhibitor Jemperli Gains Approval for Endometrial Cancer The FDA has given accelerated approval to GSK’s Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody used to treat adults with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum - containing chemotherapy treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 24, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Immunotherapy for dMMR Endometrial Cancer
FRIDAY, April 23, 2021 -- The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves New Immunotherapy for Endometrial Cancer FDA Approves New Immunotherapy for Endometrial Cancer
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Media News)
Source: Roche Media News - April 23, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Jemperli (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
London UK 22 April 2021 -- GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company’s Biologics... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 22, 2021 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study reveals the 3D structure of human uterine endometrium and adenomyosis tissue
(Niigata University) Recent advances in tissue-clearing-based 3D imaging have permitted researchers to establish a new baseline 3D structure of the endometrial glands, including the formation of a rhizome network in the stratum basalis that expands horizontally along the muscular layer. These findings have implications in understanding the mechanisms underlying normal endometrial tissue processes such as menstruation and fertilized egg implantation, and in clarifying the pathogenesis of endometrium-related diseases, notably adenomyosis, endometriosis, and endometrial cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2021 Category: International Medicine & Public Health Source Type: news

An international study reveals how the 'guardian' of the genome works
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Teams from the CNIO, the Leiden University Medical Center and the Netherlands Cancer Institute use electron cryo-electron microscopy to explain how the MutS protein, considered the 'guardian' of the genome, manages to repair the errors that can occur in DNA during cell division* An in-depth understanding of this process is essential to understand how mutations occur that can lead to the development of certain types of tumour, such as Lynch syndrome and endometrial cancer (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 6, 2021 Category: Cancer & Oncology Source Type: news

An IUD Could Ward Off Endometrial Cancer in Women at Risk
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 26, 2021 Category: Cancer & Oncology Tags: Oncology, Obstetrics, News, Source Type: news

An IUD Could Ward Off Endometrial Cancer in Women at Risk
FRIDAY, March 26, 2021 -- For some patients who have early endometrial cancer or a precancerous condition, a hysterectomy may not be a good option because of serious health issues or the desire to preserve fertility. Now, a new Australian study has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 26, 2021 Category: General Medicine Source Type: news

An IUD Could Ward Off Endometrial Cancer in Women at Risk
Title: An IUD Could Ward Off Endometrial Cancer in Women at RiskCategory: Health NewsCreated: 3/26/2021 12:00:00 AMLast Editorial Review: 3/26/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 26, 2021 Category: Cancer & Oncology Source Type: news

Endometrial cancer: Patient reduced her thickened endometrial lining naturally
ENDOMETRIAL cancer begins in the uterus - part of the female reproductive system - which the NHS regards as "common", as there are over 9,400 cases each year in the UK. Do you know the warning signs? (Source: Daily Express - Health)
Source: Daily Express - Health - March 21, 2021 Category: Consumer Health News Source Type: news

Estrogen receptor tied to outcomes in DCIS
The estrogen receptor plays a key role in predicting long-term outcomes in patient...Read more on AuntMinnie.comRelated Reading: SNMMI confirms Medicare reimbursement error for Cerianna PET aids in treatment of metastatic breast cancer patients SNMMI, Zionexa call out CMS for reimbursement error Black women die more frequently from breast cancer AI tool beats traditional breast cancer risk assessments FES-PET could predict endometrial cancer outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 16, 2021 Category: Radiology Source Type: news

EU Green Light for Dostarlimab in Some Endometrial Cancers EU Green Light for Dostarlimab in Some Endometrial Cancers
A new PD-1 antagonist, dostarlimab, has been recommended for approval for use in some women with advanced/recurrent endometrial cancer.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Sentinel lymph node mapping best approach to guide adjuvant therapy in endometrial cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

Study shows new treatment pathway to prevent and treat endometrial cancer recurrence
(Yale University) In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2021 Category: Cancer & Oncology Source Type: news

Oral Contraceptives May Reduce Cancer Risk
Oral Contraceptives May Reduce Ovarian and Endometrial Cancer Risk (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 5, 2021 Category: General Medicine Source Type: news

Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 4, 2021 Category: Internal Medicine Tags: Hematology-Oncology News Source Type: news

EIT Health invests €3M in innovations for endometrial cancer and Parkinson's disease
The Wild Card open innovation programme has selected  two innovator teams from Spain and Germany. (Source: mobihealthnews)
Source: mobihealthnews - February 1, 2021 Category: Information Technology Source Type: news

New, simplified genetic test effectively screens for hereditary cancers
(Elsevier) Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in colon, endometrial, and other cancers. This alternative to complex, multi-step testing workflows can also determine causes of MMR deficiency often missed by current clinical tests. Their results are presented in The Journal of Molecular Diagnostics, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Oral Contraceptives Tied to Lower Risk for Certain Cancers
The drugs may increase the risk of breast cancer, but may lower the risk of ovarian and endometrial cancers. (Source: NYT Health)
Source: NYT Health - January 5, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Ovarian Cancer Breast Cancer Women and Girls Deaths (Fatalities) Birth Control and Family Planning Source Type: news

Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
MONDAY, Dec. 21, 2020 -- Oral contraceptives have a lasting protective effect against ovarian and endometrial cancer, according to a study published online Dec. 17 in Cancer Research. Torgny Karlsson, Ph.D., from Uppsala University in Sweden, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Oral contraceptive pills protect against ovarian and endometrial cancer
(Uppsala University) A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Two-Drug Combo Standard of Care in Advanced Endometrial Cancer Two-Drug Combo Standard of Care in Advanced Endometrial Cancer
Survival outcomes for the combination paclitaxel-carboplatin were similar to those with paclitaxel, doxorubicin, and cisplatin but with lower toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FES-PET could predict endometrial cancer outcomes
PET imaging with the radiotracer F-18 fluoroestradiol (FES) can help determine...Read more on AuntMinnie.comRelated Reading: Imaging agent for breast cancer PET gets FDA nod FES-PET enhances treatment for metastatic breast cancer FES-PET detects estrogen-receptor-positive breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2020 Category: Radiology Source Type: news

Constitutive expression of progesterone receptor isoforms promotes the development of hormone-dependent ovarian neoplasms
Differences in the relative abundances of the progesterone receptor (PGR) isoforms PGRA and PGRB are often observed in women with reproductive tract cancers. To assess the importance of the PGR isoform ratio in the maintenance of the reproductive tract, we generated mice that overexpress PGRA or PGRB in all PGR-positive tissues. Whereas few PGRA-overexpressing mice developed reproductive tract tumors, all PGRB-overexpressing mice developed ovarian neoplasms that were derived from ovarian luteal cells. Transcriptomic analyses of the ovarian tumors from PGRB-overexpressing mice revealed enhanced AKT signaling and a gene expr...
Source: Signal Transduction Knowledge Environment - October 5, 2020 Category: Science Authors: Wetendorf, M., Li, R., Wu, S.-P., Liu, J., Creighton, C. J., Wang, T., Janardhan, K. S., Willson, C. J., Lanz, R. B., Murphy, B. D., Lydon, J. P., DeMayo, F. J. Tags: STKE Research Articles Source Type: news

Mayo Clinic Q and A: Understanding endometrial cancer
DEAR MAYO CLINIC: My 54-year-old sister was diagnosed recently with early-stage endometrial cancer. She only went to the doctor because she had bleeding between menstrual cycles. I'm wondering if I am at risk, too, and if there is anything I can do to reduce my risk. Is there a screening test? ANSWER: An increased risk for endometrial [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 29, 2020 Category: Databases & Libraries Source Type: news

Women's Wellness: Obesity increases endometrial cancer risk
Endometrial cancer, which begins in the uterus within the layer of cells that form the uterine lining, has been on the rise over the past decade. Each year in the U.S., over 60,000 women are diagnosed with endometrial cancer, also referred to as uterine cancer. Endometrial cancer is now the most common cancer to affect [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 16, 2020 Category: Databases & Libraries Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

AI spots cervical cancer lymph node metastasis on MRI
An artificial intelligence (AI) algorithm was able to preoperatively identify...Read more on AuntMinnie.comRelated Reading: Textural analysis improves breast MRI's accuracy ASTRO releases first cervical cancer guidelines Model predicts metastases in endometrial cancer patients Caution urged for breast MRI evaluation of lymph nodes AI may predict lymph node metastasis in gastric cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 24, 2020 Category: Radiology Source Type: news

Yale Cancer Center study validates combination therapy for aggressive endometrial cancer
(Yale University) Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 29, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Keytruda for Certain Mesothelioma Patients
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - June 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New, Non-Invasive Blood Test Could Assist in Early Detection of Endometrial Cancer
Researchers from a study published in Cancers discovered a new method of detecting endometrial cancer in women via a simple, non-invasive blood test. (Source: CancerNetwork)
Source: CancerNetwork - May 26, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

WHRY funds studies on stroke, endometrial cancer, and addiction to opioids
Women ’s Health Research at Yale is expanding its work to “address the enduring and pressing medical conditions that continue to affect women’s lives.” (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 21, 2020 Category: Universities & Medical Training Source Type: news

Weight Loss Intervention Fails in Endometrial Cancer Survivors Weight Loss Intervention Fails in Endometrial Cancer Survivors
Almost half of obese endometrial cancer survivors in a recent study gained weight during 12 months of follow-up, whether or not they participated in a behavioral weight loss intervention.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Philadelphia biopharm company partners with Chinese firm to advance cancer therapy
Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate. That experimental therapy, called onapristone ER, is being evaluated in mid-stage clinical testing in patients with certain types of ovarian and endometrial cancers. Context plans to conduct mid-stage clinical testing of onapristone ER in patients with breast cancer later this year. Financial… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 23, 2020 Category: Biotechnology Authors: John George Source Type: news

Philadelphia biopharm company partners with Chinese firm to advance cancer therapy
Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate. That experimental therapy, called onapristone ER, is being evaluated in mid-stage clinical testing in patients with certain types of ovarian and endometrial cancers. Context plans to conduct mid-stage clinical testing of onapristone ER in patients with breast cancer later this year. Financial… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 23, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors
(University of Texas M. D. Anderson Cancer Center) Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors. Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news

Risk factors for endometrial cancer identified
A study published in theJournal of Medical Genetics identifies risk factors for endometrial cancer that could help develop targeted screening and prevention strategies.Science Codex (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 19, 2020 Category: Endocrinology Source Type: news

Twenty four genetic variants linked to heightened womb cancer risk
(BMJ) Twenty four common variations in genes coding for cell growth and death, the processing of oestrogen, and gene control factors may be linked to a heightened risk of developing womb (endometrial) cancer, indicates the most comprehensive review of the published evidence so far in the Journal of Medical Genetics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2020 Category: International Medicine & Public Health Source Type: news

Study identifies risk factors for endometrial cancer
(University of Manchester) An analysis of 149 scientific studies has identified 24 genetic variants which predispose women to endometrial cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 17, 2020 Category: Biology Source Type: news

Study surveys molecular landscape of endometrial cancer
(NYU Langone Health / NYU School of Medicine) The most comprehensive molecular study of endometrial cancer to date has further defined the contributions of key genes and proteins to the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

New, detailed molecular roadmap boosts fight against endometrial cancer
(DOE/Pacific Northwest National Laboratory) Scientists have taken an unprecedented look at the proteins involved in endometrial cancer, commonly known as uterine cancer. The study offers insights about how physicians might be able to better identify which patients will need aggressive treatment and which won't, and offers clues about why a common cancer treatment is not effective with some patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news